Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$14.61 USD
+0.33 (2.31%)
Updated Sep 24, 2024 01:14 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 441 - 460 ( 729 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Launched for Oral Surgery Pain Management; Reiterate OUTPERFORM and $109 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Estimates for Q3 EXPAREL Sales Are Tracking About -7.6% Below Consensus but Seasonal; Reiterate OUTPERFORM and $109 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health EXPAREL Estimate ~1.5% Below Consensus but Accelerating Sales per Day; Reiterate OUTPERFORM and $109 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Solid Q2 Beat Consensus--We See Increasing Demand for Opioid Sparing Pain Management Using EXPAREL; Reiterate OUTPERFORM and Increasing PT to $109
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 Preview: Symphony Health Update for June Exparel Sales Estimate Suggests Q2 Within 1.63% of Consensus; Reiterate OUTPERFORM and $105 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May Symphony Health Estimate Suggests 0.8% Growth Over April and Tracking about 1.2% from Consensus; Reiterate OUTPERFORM and $105 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D